Compare AHT & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHT | ITRM |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 24.3M |
| IPO Year | 2003 | 2018 |
| Metric | AHT | ITRM |
|---|---|---|
| Price | $3.88 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 344.8K | ★ 1.2M |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,119,102,000.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.36 |
| 52 Week High | $10.35 | $2.18 |
| Indicator | AHT | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 39.30 |
| Support Level | $3.05 | $0.44 |
| Resistance Level | $4.80 | $0.49 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 51.89 | 15.81 |
Ashford Hospitality Trust Inc. is a real estate investment trust that invests in full-service upscale and upper-upscale hotel properties in the U.S. The company owns and operates its assets through its operating partnership, Ashford Hospitality Limited Partnership. All of its hotels are located across the U.S. and operate under the Marriott, Hilton, Hyatt, Crowne Plaza, and Sheraton brands. Ashford's sole segment is Direct Hotel Investments, through which it owns hotels by acquisition or development. Ashford also provides real estate investment services, such as mezzanine financing, first mortgage financing, and sales-leaseback transactions. Its revenue streams include Room revenue, Food and beverage revenue, and Other revenue. Room revenue accounts for the majority of total revenue.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.